114165-30-9

Usage

Uses

Used in Chemical Research:
1-ACETYL-5-BROMO-3-HYDROXYINDOLE is used as a reagent/reactant for vibrational spectroscopic studies of N1-ethyl-5''-bromo-7-azaindirubin 3''-oxime and N1-ethyl-indirubin 3''-monooxime. This application is important for understanding the molecular interactions and properties of these compounds, which can be crucial in the development of new materials and pharmaceuticals.
Used in Pharmaceutical Industry:
1-ACETYL-5-BROMO-3-HYDROXYINDOLE may also be used as a starting material or intermediate in the synthesis of various pharmaceutical compounds. Its unique structural features make it a valuable candidate for the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Material Science:
Due to its structural properties, 1-ACETYL-5-BROMO-3-HYDROXYINDOLE could potentially be used in the development of new materials with specific properties, such as optical, electronic, or mechanical characteristics. This application could be particularly relevant in industries such as electronics, aerospace, or automotive, where advanced materials are constantly in demand.

InChI:InChI=1/C10H8BrNO2/c1-6(13)12-5-10(14)8-4-7(11)2-3-9(8)12/h2-5,14H,1H3

Upstream product

• 33588-54-4 5-bromoindoxyl diacetate 
• 2897-43-0 2,6-dichloro-3-nitropyridin-4-amine 
• 2402-78-0 2,6-dichloropyridine 
• 2587-02-2 2,6-dichloro-[4]pyridylamine 
• 25194-01-8 4-nitro-2,6-dichloro-pyridine 
• 32253-75-1 5-bromo-2-<(carboxymethyl)amino>-benzoic acid 
• 108-24-7 acetic anhydride 
• 868694-19-3 5-bromo-3-iodo-1H-indole 
• 17357-14-1 5-bromo-3-indoxyl acetate 
• 10075-50-0 5-bromo-1H-indole 
• 2587-03-3 2,6-dichloro-N-nitro-4-pyridinamine 
• 2587-00-0 2,6-dichloropyridine N-oxide 
• 668268-66-4 3-amino-4-acetamido-2,6-dichloropyridine 

Downstream Products

• 203447-96-5 5-bromoindol-3-yl 5-acetamido-4,7-di-O-methyl-3,5-dideoxy-D-glycero-D-galacto-nonulopyranosidonic acid 
• 1396341-18-6 (Z)-2-(4-(methylamino)benzylidene)-1-acetyl-5-bromoindolin-3-one 
• 1396341-19-7 (Z)-2-(4-(dimethylamino)benzylidene)-1-acetyl-5-bromoindolin-3-one 
• 960155-08-2 1-benzyl-5'-bromo-7-azaindirubin 

Relevant academic research and scientific papers

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) plays a role in receptor tyrosine kinase (RTK), neurofibromin-1 (NF-1), and Kirsten rat sarcoma virus (KRAS) mutant-driven cancers, as well as in RTK-mediated resistance, making the identification of small-molecule therapeutics that interfere with its function of high interest. Our quest to identify potent, orally bioavailable, and safe SHP2 inhibitors led to the discovery of a promising series of pyrazolopyrimidinones that displayed excellent potency but had a suboptimal in vivo pharmacokinetic (PK) profile. Hypothesis-driven scaffold optimization led us to a series of pyrazolopyrazines with excellent PK properties across species but a narrow human Ether-à-go-go-Related Gene (hERG) window. Subsequent optimization of properties led to the discovery of the pyrimidinone series, in which multiple members possessed excellent potency, optimal in vivo PK across species, and no off-target activities including no hERG liability up to 100 μM. Importantly, compound 30 (IACS-15414) potently suppressed the mitogen-activated protein kinase (MAPK) pathway signaling and tumor growth in RTK-activated and KRASmut xenograft models in vivo.

HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38

The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold hopping. Further optimization led to the discovery of 40 (GLPG2938), a compound with exquisite potency on a phenotypic IL8 release assay, good pharmacokinetics, and good activity in a bleomycin-induced model of pulmonary fibrosis.

CDK INHIBITORS

Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.

FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR

Disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an application of the compound or slat in preparation of drugs for treating diseases related to an A2A receptor.

AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS

The present invention relates to azabenzimidazole derivatives of Formula (I) (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3Kβ inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active 10 ingredient as well as the use of said compounds as a medicament.

Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors

Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causative mechanisms for the observed PK. The series also harbored the CYP3A4 TDI liability driven by the presence of both a morpholine and an indole moiety. Incorporation of an adjacent fluorine or nitrogen into the 6-azaindole addressed many of the various medicinal chemistry issues encountered. (Chemical Presented).

Araf51 with improved transglycosylation activities: One engineered biocatalyst for one specific acceptor

A random mutagenesis of the arabinofuranosyl hydrolase Araf51 has been run in order to have access to efficient biocatalysts for the synthesis of alkyl arabinofuranosides. The mutants were selected on their ability to catalyze the transglycosylation reaction of p-nitrophenyl α-l-arabinofuranoside (pNP-Araf) used as a donor and various aliphatic alcohols as acceptors. This screening strategy underlined 5 interesting clones, each one corresponding to one acceptor. They appeared to be much more efficient in the transglycosylation reaction compared to the wild type enzyme whereas no self-condensation or hydrolysis products could be detected. Moreover, the high specificity of the mutants toward the alcohols for which they have been selected validates the screening process. Sequence analysis of the mutated enzymes revealed that, despite their location far from the active site, the mutations affect significantly the kinetics properties as well as the substrate affinity of these mutants toward the alcohol acceptors in the transglycosylation reaction.

PYRIDO[3,4-B]PYRAZINE DERIVATIVES AS SYK INHIBITORS

A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (Syk) and therefore potentially of use in treating diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for instance inflammatory disease and/or allergic disorders, and in cancer therapy, specifically heme malignancies, and autoimmune conditions.

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.